Gregg Gilbert
Stock Analyst at Truist Securities
(2.28)
# 2,568
Out of 4,711 analysts
91
Total ratings
53.7%
Success rate
5.14%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
DHT DHT Holdings | Maintains: Buy | $14 → $17 | $8.95 | +89.94% | 2 | Feb 16, 2024 | |
COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $29.70 | +24.58% | 1 | Jan 4, 2024 | |
BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $57.33 | +46.52% | 9 | Sep 15, 2023 | |
LLY Eli Lilly | Maintains: Buy | $430 → $525 | $767.76 | -31.62% | 10 | Jul 20, 2023 | |
EOLS Evolus | Maintains: Buy | $11 → $13 | $10.89 | +19.38% | 2 | Mar 4, 2022 | |
NVCR NovoCure | Upgrades: Buy | n/a | $30.80 | - | 10 | Jan 20, 2022 | |
MRK Merck & Co. | Maintains: Buy | $96 → $93 | $98.05 | -5.15% | 8 | Jun 7, 2021 | |
ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $14.99 | +220.21% | 2 | Feb 2, 2021 | |
CHRS Coherus BioSciences | Initiates: Buy | $26 | $1.52 | +1,610.53% | 1 | Apr 17, 2020 | |
MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.55 | +27,422.93% | 1 | Jan 24, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $25.75 | +202.91% | 17 | Aug 10, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $164.84 | -52.68% | 5 | Feb 16, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $22.09 | -18.52% | 6 | Feb 9, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $114.64 | - | 7 | Nov 20, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $122.97 | +42.31% | 6 | Aug 9, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $175.58 | -62.41% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $8.95
Upside: +89.94%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $29.70
Upside: +24.58%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $57.33
Upside: +46.52%
Eli Lilly
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $767.76
Upside: -31.62%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $10.89
Upside: +19.38%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $30.80
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $98.05
Upside: -5.15%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $14.99
Upside: +220.21%
Coherus BioSciences
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.52
Upside: +1,610.53%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.55
Upside: +27,422.93%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $25.75
Upside: +202.91%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $164.84
Upside: -52.68%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $22.09
Upside: -18.52%
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $114.64
Upside: -
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $122.97
Upside: +42.31%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $175.58
Upside: -62.41%